SW-1573 Cells

Categories: Lung cancer cell lines , Human cells Description: SW-1573 is a human non-small cell lung carcinoma (NSCLC) cell line derived from the lung tissue of a female patient diagnosed with squamous cell carcinoma. This cell line has been extensively characterized for its genetic, biochemical, and pharmacological properties, making it a valuable model for studying lung cancer biology and drug responses. SW-1573 is known for its epithelial morphology and moderate growth rate in vitro. It has been included in numerous studies to assess the impact of chemotherapeutic agents and targeted therapies in lung cancer. Genomic analyses of SW-1573 have revealed key mutations relevant to NSCLC pathogenesis. Studies have shown that SW-1573 lacks common driver mutations in KRAS and EGFR, which distinguishes it from other NSCLC cell lines that are frequently used in lung cancer research. Instead, it carries other genomic alterations that contribute to tumor progression and drug resistance. Large-scale pharmacogenomic efforts, such as those in the Cancer Cell Line Encyclopedia (CCLE), have assessed its drug sensitivity profile, identifying vulnerabilities to specific cytotoxic agents and small-molecule inhibitors. SW-1573 has been employed in radiation biology studies, as it has demonstrated varying sensitivity to ionizing radiation. Researchers have used this cell line to investigate DNA damage response mechanisms and the role of cell cycle checkpoints in lung cancer therapy. Furthermore, enzyme polymorphism studies have confirmed its genetic stability and distinct identity among other tumor-derived cell lines, ensuring its reliability as a research tool. Organism: Human Tissue: Lung Disease: Minimally invasive adenocarcinoma, Alveolar Cell Synonyms: SW-1573, SW 1573 Age: 44 years Gender: Female Ethnicity: Caucasian Morphology: epithelial Growth Properties: Adherent Citation: SW-1573 (Cytion catalog number 305644) Biosafety Level: 1 Ncbi_ Taxid: 9606.0 Cellosaurus Accession: CVCL_1720 Antigen Expression: Blood Type O, Rh + Mutational Profile: Gene deletion: CDKN2A, Homozygous, .Gene deletion: SMAD4, Homozygous, Mutation: CTNNB1, Simple, p.Ser33Phe (c.98C>T), Heterozygous, Mutation: KRAS, Simple, p.Gly12Cys (c.34G>T), Homozygous, Mutation: PIK3CA, Simple, p.Lys111Glu (c.331A>G), Heterozygous, Mutation: SMARCB1, Simple, c.362+1G>C, Heterozygous, Note=Splice donor mutation (Cosmic-CLP=724878). Culture Medium: RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) Supplements: Supplement the medium with 10% FBS Dissociation Reagent: Accutase Doubling Time: 23 hours Freeze Medium: As a cryopreservation medium, use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Thawing And Culturing Cells: Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently. Centrifuge the mixture at 300 x g for 3 minutes to separate the cells and carefully discard the supernatant containing residual freezing medium. Gently resuspend the cell pellet in 10 ml of fresh culture medium. For adherent cells, divide the suspension between two T25 culture flasks, for suspension cultures, transfer all the medium into one T25 flask to promote effective cell interaction and growth. Adhere to established subculture protocols for continued growth and maintenance of the cell line, ensuring reliable experimental outcomes. Sterility: Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. Safety Precautions: When planning to store a cryovial in liquid nitrogen for future thawing, it is mandatory to adhere to stringent safety measures. Appropriate protective gloves and clothing are essential, and the use of a face mask or safety goggles is required during the transfer of frozen samples to or from the liquid nitrogen tank. This is to mitigate the risk of injury from potential cryovial explosions upon removal, which can result in the projection of sharp fragments. Warranty: We stand by the promise of delivering products with high cell viability and robust culture performance. To achieve the best results, please make sure you follow the storage and culture instructions detailed in the product information sheet closely. Your adherence to these guidelines is key to success. Subject To Material Transfer Agreements: If you intend to use Cytion cell lines solely for internal research at a single research site, please complete and sign our Material Transfer Agreement (MTA) and submit it along with your order.For any commercial applications - including but not limited to fee-for-service work, quality control testing, product release, diagnostic use, or regulatory studies - please complete the Intended Use Form so we can prepare a suitable agreement tailored to your project.Please note: The MTA applies only to certain cell lines. If this notice and the MTA document appear on a product page, the agreement is applicable. For cell lines not covered by the MTA, no reference to the agreement will be shown. The MTA is not valid for customers in the Americas, China, or Taiwan. Please contact our U.S. entity to receive the appropriate agreement. Required Product 3: 860015.0 Required Product 4: 830100.0